AdaptHealth (AHCO)
NASDAQ:AHCO
Want to see AHCO full AI Analyst Report?
AHCO Stock Chart & Stats
$12.66
$0.16(1.59%)
At close: 4:00 PM EST
$12.66
$0.16(1.59%)
Day’s Range― - ―
52-Week Range$8.06 - $13.43
Previous CloseN/A
Volume245.49K
Average Volume (3M)1.46M
Market Cap
$1.54B
Enterprise Value$1.69B
Total Cash (Recent Filing)$47.96M
Total Debt (Recent Filing)$2.00B
Price to Earnings (P/E)―
Beta0.37
Next Earnings
Aug 11, 2026EPS Estimate
0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding136,054,150
10 Day Avg. Volume1,148,342
30 Day Avg. Volume1,464,059
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.89
Price to Sales (P/S)0.41
P/FCF Ratio6.14
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue0.59
Enterprise Value/Gross Profit10.98
Enterprise Value/Ebitda3.53
Forecast
1Y Price Target
$13.64Price Target Upside7.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)0.9
Revenue Forecast (FY)$3.48B
Bulls Say, Bears Say
Bulls Say
Core Business FocusAdapt is focusing on core business areas like Sleep, Respiratory, Diabetes, and Wellness at Home, which is leading to improved financial performance and patient service.
Deleveraging EffortsAdapt's deleveraging efforts are reducing the company's risk profile, which could lead to multiple expansion in the future.
Technology And AI ImplementationThe reorganization and standardization efforts are expected to enable effective implementation of AI and technology, improving margins and insulating profitability.
Bears Say
Earnings PerformanceEPS of $0.11 came in below both the estimate and consensus.
EBITDA ForecastsLowering estimates for 2025-26 EBITDA forecasts, which affects the financial outlook despite maintaining the price target.
Revenue OutlookAdapthealth lowered its 2025 revenue outlook by about 1% at the midpoint.
AdaptHealth News
AHCO FAQ
What was AdaptHealth’s price range in the past 12 months?
AdaptHealth lowest stock price was $8.06 and its highest was $13.43 in the past 12 months.
What is AdaptHealth’s market cap?
AdaptHealth’s market cap is $1.54B.
When is AdaptHealth’s upcoming earnings report date?
AdaptHealth’s upcoming earnings report date is Aug 11, 2026 which is in 93 days.
How were AdaptHealth’s earnings last quarter?
AdaptHealth released its earnings results on May 05, 2026. The company reported -$0.056 earnings per share for the quarter, missing the consensus estimate of $0.012 by -$0.068.
Is AdaptHealth overvalued?
According to Wall Street analysts AdaptHealth’s price is currently Undervalued.
Does AdaptHealth pay dividends?
AdaptHealth does not currently pay dividends.
What is AdaptHealth’s EPS estimate?
AdaptHealth’s EPS estimate is 0.16.
How many shares outstanding does AdaptHealth have?
AdaptHealth has 136,054,150 shares outstanding.
What happened to AdaptHealth’s price movement after its last earnings report?
AdaptHealth reported an EPS of -$0.056 in its last earnings report, missing expectations of $0.012. Following the earnings report the stock price went down -9.893%.
Which hedge fund is a major shareholder of AdaptHealth?
Currently, no hedge funds are holding shares in AHCO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AdaptHealth Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.64 (7.76% Upside)
$13.64 (7.76% Upside)
Blogger Sentiment
Bullish
AHCO Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 771.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $24.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 9.8%
Last 30 Days ▼ 3.5%
Last 30 Days ▼ 3.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.51%
12-Months-Change
Fundamentals
Return on Equity
-5.24%
Trailing 12-Months
Asset Growth
-0.30%
Trailing 12-Months
Company Description
AdaptHealth
AdaptHealth Corp., together with its subsidiaries, provides home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps to patients for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs. It serves beneficiaries of Medicare, Medicaid, and commercial insurance payors. AdaptHealth Corp. is headquartered in Plymouth Meeting, Pennsylvania.
AHCO Company Deck
AHCO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights a major strategic win — completion of a large capitated transition, robust organic revenue growth (9.1% y/y), strong segment performance (notably Sleep and Respiratory), important technology milestones, and a refinancing that improves financial flexibility. Near-term challenges include elevated transition-related labor costs ($12M), a Q1 adjusted EBITDA miss (~$7M), negative free cash flow in the quarter due to elevated CapEx ($121.2M), and a temporary increase in leverage to ~3.0x. Management expects labor costs and CapEx to normalize by mid-year, maintains full-year EBITDA and free cash flow guidance, and raised revenue guidance slightly. Overall, strategic progress and forward-looking actions appear to outweigh the near-term execution and cash impacts.View all AHCO earnings summariesAHCO Stock 12 Month Forecast
Average Price Target
$13.64
▲(7.76% Upside)
Technical Analysis
Ownership Overview
15.03% Insiders
22.38% Mutual Funds
21.06% Other Institutional Investors
18.80% Public Companies and
Individual Investors